natgillin/translations-raw huggingface dataset:
Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
Bevacizumab je u kombinaciji s kemoterapijom na bazi spojeva platine indiciran za prvu liniju liječenja odraslih bolesnika s neresektabilnim uznapredovalim, metastatskim ili recidivirajućim karcinomom pluća nemalih stanica u kojemu histološki ne prevladavaju skvamozne stanice.
Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.
Bevacizumab je u kombinaciji s karboplatinom i gemcitabinom indiciran za liječenje odraslih bolesnica s prvim recidivom epitelnog karcinoma jajnika, karcinoma jajovoda ili primarnog peritonealnog karcinoma osjetljivih na platinu, koje prethodno nisu bile liječene bevacizumabom, drugim VEGF inhibitorima niti lijekovima koji djeluju na VEGF receptore.
Beware: Artificial sweeteners and foods with artificial sweeteners (such as diet drinks) are of no help in treating hypoglycaemia.
Oprez: Umjetni zaslađivači i hrana zaslađena umjetnim zaslađivačima (primjerice dijetna pića) ne pomažu u slučaju hipoglikemije.
Bexarotene has a different adverse reaction profile to other oral, non-retinoid X receptor (RXR) - selective retinoids.
Beksaroten ima različit profil nuspojava od drugih peroralnih retinoida koji nisu selektivni za retinoidni X receptor (RXR).
Bexarotene may potentially enhance the action of insulin, agents enhancing insulin secretion (e.g. sulfonylureas), or insulin-sensitisers (e.g. thiazolidinediones), resulting in hypoglycaemia (see section 4.4).
Beksaroten može potencijalno pojačati djelovanje inzulina, lijekova koji pojačavaju lučenje inzulina (npr. sulfonilureje) ili lijekova koji povećavaju osjetljivost na inzulin (npr. tiazolidindioni) što rezultira hipoglikemijom (vidjeti dio 4.4).
Bexarotene therapy should only be initiated and maintained by physicians experienced in the treatment of patients with CTCL.
Terapiju beksarotenom smiju propisivati i provoditi samo liječnici s iskustvom u liječenju bolesnika s kožnim limfomom T-stanica (engl. cutaneous T-cell lymphoma, CTCL).
Bexsero can be given at the same time as any of the following vaccine components: diphtheria, tetanus, whooping cough (pertussis), Haemophilus influenzae type b, polio, hepatitis B, pneumococcus, measles, mumps, rubella, chickenpox, and meningococcus C. Talk to your doctor or nurse for further information.
Bexsero se smije dati istodobno s bilo kojim sastojkom slijedećih cjepiva: difterija, tetanus, hripavac (pertusis), Haemophilus influenzae tip b, polio, hepatitis B, pneumokok, ospice, zaušnjaci, rubeola, vodene kozice i meningokok C. Razgovarajte sa svojim liječnikom ili medicinskom sestrom za dodatne informacije.
Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines: diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis B, heptavalent pneumococcal conjugate, measles, mumps, rubella, varicella, and meningococcal group C-CRM conjugate.
Bexsero se može primjenjivati istodobno s bilo kojim antigenom sljedećih cjepiva, bilo kao monovalentno ili kao kombinirano cjepivo protiv: difterije, tetanusa, pertusisa (nestanično), hemofilusa tipa b, poliomijelitisa (inaktivirano), hepatitisa B, pneumokoka (sedmerovalentno, konjugirano), morbila, parotitisa, rubele, varičela i meningokoka (konjugirano grupe C- CRM).
Bexsero contains four different components from the surface of the bacteria Neisseria meningitidis group B.
Bexsero sadrži četiri različita sastojka iz površine bakterije Neisseria meningitidis grupe B.
Bexsero is a Meningococcal group B Vaccine.
Bexsero je cjepivo protiv meningokoka grupe B.
Bexsero is a suspension for injection in pre-filled syringe (Type I glass) with a plunger stopper (Type I bromobutyl rubber) and with a protective tip cap (Type I or Type II rubber) with or without needles.
Bexsero je suspenzija za injekciju u napunjenoj štrcaljki (staklo tipa I) s čepom klipa (bromobutilna guma tip I) i zaštitnim zatvaračem vrha (guma tipa I ili tipa II) sa ili bez igala.
Bexsero is a vaccine which is available as a suspension for injection in a pre-filled syringe.
Bexsero je cjepivo koje je dostupno kao suspenzija za injekciju u prethodno napunjenoj štrcaljki.
Bexsero is given by deep injection into a muscle, preferably into the shoulder muscle, or into the thigh muscle in children under two years old.
Bexsero se primjenjuje dubinskom injekcijom u mišić, po mogućnosti u mišić ramena ili u mišić bedra u djece mlađe od dvije godine.
Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B. The impact of invasive disease in different age groups as well as the variability of antigen epidemiology for group B strains in different geographical areas should be considered when vaccinating.
Bexsero je indiciran za aktivnu imunizaciju osoba u dobi od 2 mjeseca i starijih protiv invazivne meningokokne bolesti uzrokovane bakterijom Neisseria meningitidis grupe B. Prilikom cijepljenja potrebno je uzeti u obzir učinak invazivne bolesti u različitim dobnim skupinama kao i varijabilnost epidemiologije antigena za sojeve grupe B u različitim geografskim područjima.
Bexsero is not expected to provide protection against all circulating meningococcal group B strains (see section 5.1).
Bexsero nije predviđen za pružanje zaštite od svih cirkulirajućih sojeva meningokoka grupe B (vidjeti dio 5.1).
Bexsero is used to protect individuals from the age of two months against invasive meningococcal disease caused by one group of the bacterium N. meningitidis (group B).
Bexsero se koristi za zaštitu bolesnika u dobi od dva mjeseca i starijih od invazivne bolesti uzrokovane jednom grupom bakterije N. meningitidis (grupa B).
Bexsero meningococcal group B vaccine (rDNA, component, adsorbed)
Bexsero cjepivo protiv meningokoka grupe B (rDNK, komponentno, adsorbirano)
Bexsero should be used according to official recommendations.
Bexsero se daje u skladu sa službenim preporukama.
BIA 9-1103 plasma levels were not affected in patients with chronic renal impairment, and as such, no dose adjustment needs to be considered.
Razine BIA 9- 1103 u plazmi nisu bile promijenjene u bolesnika s kroničnim oštećenjem funkcije bubrega te stoga nema potrebe prilagođavati dozu.
BIAL-Portela & Cª, S.A. Tel.: + 351 22 986 61 00 (Portugália)
Tel: + 43 (0) 1 535 1980-0
BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Portugal)
BIAL - Portela & Cª , S.A tel: +351 22 986 61 00
BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Portugal)
BIAL - Portela & Cª , S.A tel: +351 22 986 61 00 (Portugal)
BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Portugalia)
BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Portugal) (Portugalia)
BIAL-Portela & Cª., S.A. Tel.: + 351 22 986 61 00
BIAL-Portela & Cª, S.A. Tel.: + 351 22 986 61 00 (Portugália)
BIAsp 30 (b.i.d.)1
BIAsp 30 (d.d.)1
BIAsp 30 (b.i.d.)2
BIAsp 30 (d.d.)2
bicarbonate
toplinski udar
Bicarbonate should be administered at least one hour before or one hour after PROCYSBI to avoid potential earlier release of cysteamine
Bikarbonati se moraju davati najmanje jedan sat prije ili jedan sad nakon lijeka PROCYSBI kako bi se izbjeglo potencijalno prerano oslobađanje cisteamina.
Bicytopenia, leukopenia
Bicitopenija, leukopenija
BID has not been studied.
2x dnevno.
BID) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.
Istodobnu primjenu vorikonazola i niske doze ritonavira (100 mg BID) treba izbjegavati, osim kad procjena odnosa koristi i rizika za bolesnika opravdava primjenu vorikonazola.
BIGUANIDE ORAL ANTIHYPERGLYCEMICS
ANTIHIPERLIPEMICI
BIGUANIDE ORAL ANTIHYPERGLYCEMICS
BIGVANIDNI ORALNI ANTIHIPERGLIKEMICI
Bilateral treatment
Primjena u oba oka
Bile acid malabsorption
Malapsorpcija žučne kiseline
Bile acid resin
Smole žučnih kiselina
Bile acid resins such as colestyramine/colestipol (a medicine for lowering cholesterol), because it affects the way Pravafenix works.
molama žučnih kiselina poput kolestiramina/kolestipola (lijeka za snižavanje kolesterola), jer utječe na način djelovanja Pravafenixa,
Bile acid sequestrants, such as cholestyramine, can remove MPA by decreasing the enterohepatic re- circulation of the drug (see section 5.2).
Lijekovi za snižavanje razine žučnih kiselina, npr. kolestiramin, mogu ukloniti MPA smanjivanjem enterohepatične recirkulacije lijeka (vidjeti dio 5.2).
Bile acid sequestrants, such as cholestyramine, can remove MPA by decreasing the enterohepatic re- circulation of the drug (see section 5.2)..
Lijekovi za snižavanje razine žučnih kiselina, npr. kolestiramin, mogu ukloniti MPA smanjivanjem enterohepatične recirkulacije lijeka (vidjeti dio 5.2).
Bile duct cancer, diffuse large B-cell lymphoma, Hodgkin’s disease, metastases to bone, metastases to liver, metastases to peritoneum, nasopharyngeal cancer, oesophageal carcinoma
Karcinom žučnih vodova, difuzni limfom velikih B-stanica, Hodgkinova bolest, metastaze kostiju, metastaze jetre, peritonealne metastaze, nazofaringealni karcinom, ezofagealni karcinom
bile duct disorders,
poremećaji žučnih
bile duct disorders, hepatocellular damage and hepatitis, cholestasis and jaundice
poremećaji žučovoda, hepatocelularno oštećenje i hepatitis, kolestaza i žutica
bile duct disorders, yellowing of the skin due to liver problems, liver tissue damage and inflammation of the liver
poremećaji žučnih putova, žuta boja kože zbog problema s jetrom, oštećenje tkiva jetre i upala jetre
Bile duct disorders, yellowing of the skin due to liver problems, liver tissue damage and inflammation of the liver
poremećaji žučovoda, žuta boja kože zbog tegoba s jetrom, oštećenje tkiva jetre i upala jetre
Bile flow does not influence the absorption of tacrolimus and therefore treatment with Advagraf may commence orally.
Protok žuči ne utječe na apsorpciju takrolimusa, pa se stoga liječenje može započeti peroralnom primjenom Advagrafa.
bile problems
problemi sa žuči
Bile salt- sequestering agents such as cholestyramine and cholestagel may interact with regorafenib by forming insoluble complexes which may impact absorption (or reabsorption), thus resulting in potentially decreased exposure.
Može doći do interakcije lijekova za odjeljivanje žučnih soli kao što su kolestiramin i kolestipol sa regorafenibom sa stvaranjem netopljivih kompleksa koji mogu utjecati na apsorpciju (ili reapsorpciju), odnosno potencijalno dovesti do smanjenja izloženosti.
Bile salt-sequestering agents
Lijekovi za odjeljivanje žučnih soli
Bile salt-sequestering agents
Sekvestranti žučne kiseline
Biliary dilatation
dilatacija žučnih vodova
Biliary dilatation
jetre i žuči
Biliary excretion of the unchanged drug substance was the major route of elimination.
Glavni put izlučivanja proizvoda je bilijarna ekskrecija.
Biliary excretion of unchanged compound may be an important route of elimination.
Izlučivanje nepromijenjenog spoja putem žuči može predstavljati važan put eliminacije.
Biliary hyperplasia was observed in cynomolgus monkeys given efavirenz for � 1 year at a dose resulting in mean AUC values approximately 2-fold greater than those in humans given the recommended dose.
Bilijarna hiperplazija opažena je u makaki majmuna koji su efavirenz primali ≥1 godine u dozama kojima je postignut približno dvostruko viši prosječni AUC od onog u ljudi koji su primali preporučenu dozu lijeka.
Biliary obstruction
bilijarna opstrukcija
Biliary obstructive disorders
Bilijarni opstruktivni poremećaji
Biliary obstructive disorders
Bilijarni opstruktivni poremećaji.
Biliary obstructive disorders and severe hepatic impairment
Bilijarna opstrukcija i teško oštećenje jetre
bilirubin
povišen ukupni bilirubin
Bilirubin <1.25 X upper normal limit
Bilirubin < 1,25 puta gornja normalna granica
Bilirubin conjugated increased (with or without concomitant increase of ALT)
Povišeni konjugirani bilirubin (sa ili bez istodobnog porasta ALT-a)
Bilirubin increased
povišenje
Bilirubin increased
povišenje bilirubina
Bilirubin increased, alkaline phosphatase increased
povišen bilirubin, povišena alkalna fosfataza
bilirubin increased, alkaline phosphatase increased, GGT
povišen AST, povišen bilirubin, povišena alkalna fosfataza,
Bilirubin peaks approximately a week after onset and resolves approximately two weeks after onset.
Vršne vrijednosti bilirubina postižu se tjedan dana nakon nastupa i normaliziraju se približno dva tjedna nakon nastupa poremećaja.
Bilirubin – Direct
Direktni bilirubin
Bilirubin – Indirect
Bilirubin – indirektni
Bilirubin – indirect
Indirektni bilirubin
Bimatoprost 0.3 mg/ml (multi-dose and single-dose formulations)
Bimatoprost 0,3 mg/ml (višedozni i jednodozni pripravci)
Bimatoprost belongs to a group of medicines called prostamides, a prostaglandin analogue.
Bimatoprost pripada skupini lijekova koja se naziva prostamidi, analozi prostaglandina.
Bimatoprost did not impair fertility in rats up to doses of 0.6 mg/kg/day (at least 103-times the intended human exposure).
Bimatoprost nije izazvao oštećenje plodnosti u štakora u dozama do 0,6 mg/kg/dan (što je najmanje 103 puta namjeravana izloženost kod ljudi).
Bimatoprost is a potent ocular hypotensive active substance.
Bimatoprost je potentna očna hipotenzivna djelatna tvar.
Bimatoprost is a prostaglandin analogue, (a copy of the natural substance prostaglandin) that works by increasing the drainage of fluid out of the eye.
Bimatoprost je analogan prostaglandinu (kopija prirodne tvari prostaglandina) koji djeluje povećanim izlučivanjem tekućine iz oka.
Bimatoprost is biotransformed by any of multiple enzymes and pathways, and no effects on hepatic drug metabolising enzymes were observed in preclinical studies.
Bimatoprost se biotransformira preko mnogih enzima i puteva razgradnje; u nekliničkim ispitivanjima nisu zabilježeni učinci na jetrene enzime koji metaboliziraju lijekove.
Bimatoprost is eliminated primarily by renal excretion, up to 67% of an intravenous dose administered to healthy adult volunteers was excreted in the urine, 25% of the dose was excreted via the faeces.
Bimatoprost se primarno eliminira izlučivanjem putem bubrega, do 67% intravenske doze primijenjene na zdravim odraslim dobrovoljcima izlučilo se u mokraći, a 25% doze izlučilo se putem stolice.
Bimatoprost is moderately distributed into body tissues and the systemic volume of distribution in humans at steady-state was 0.67 l/kg.
Bimatoprost se umjereno distribuira u tjelesnim tkivima te je sistemski volumen distribucije kod ljudi nakon stabilizacije iznosio 0,67 l/kg.
Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing.
Nakon okularne primjene, kada dosegne sistemsku cirkulaciju, bimatoprost je glavna tvar koja cirkulira tijelom.
Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing.
Nakon primjene u oko, kada dospije u cirkulaciju, bimatoprost je glavna tvar koja cirkulira tijelom.
Bimatoprost on its own has already been approved in the European Union under the name Lumigan.
Bimatoprost je kao takav već odobren u Europskoj uniji pod nazivom Lumigan.
Binding antibodies do occur as expected with all biologics; however, they have not been associated with neutralising activity at present.
Vezivanje protutijela događa se u skladu s očekivanim za sve ostale biološke lijekove; međutim, za sada nije povezano s neutralizirajućom aktivnosti.
Binding of pazopanib to human plasma protein in vivo was greater than 99 % with no concentration dependence over the range of 10-100 g/ml.
Vezanje pazopaniba za protein u ljudskoj plazmi in vivo bilo je veće od 99%, neovisno o koncentraciji u rasponu od 10-100 g/ml.
Binding of stavudine to serum proteins was negligible over the concentration range of 0.01 to 11.4 µg/ml.
Vezanje stavudina na serumske proteine bilo je neznatno u rasponu koncentracija 0,01-11,4 μg/ml.
Binding of thyrotropin alfa to TSH receptors on thyroid epithelial cells stimulates iodine uptake and organification, and synthesis and release of thyroglobulin, triiodothyronine (T3) and thyroxine (T4).
Vezivanje tireotropina alfa na TSH receptore epitelnih stanica štitnjače stimulira pohranu i organifikaciju joda u štitnjači te sintezu i otpuštanje tireoglobulina, trijodtironina (T3) i tiroksina (T4).
Binding of VEGF-A to its receptors leads to endothelial cell proliferation and neovascularisation, as well as vascular leakage, all of which are thought to contribute to the progression of the neovascular form of age-related macular degeneration, pathologic myopia or to visual impairment caused by either diabetic macular oedema or macular oedema secondary to RVO.
Vezanjem VEGF-A na njegove receptore dolazi do proliferacije endotelnih stanica i neovaskularizacije, te se povećava vaskularna propusnost, a smatra se da to sve doprinosi razvoju neovaskularnog oblika senilne makularne degeneracije, patološke miopije ili nastanku poremećaja vida uzrokovanog bilo dijabetičkim makularnim edemom, bilo makularnim edemom posljedičnim RVO-u.
Binding studies indicate that agomelatine has no effect on monoamine uptake and no affinity for ,  adrenergic, histaminergic, cholinergic, dopaminergic and benzodiazepine receptors.
Ispitivanje reakcije vezanja ukazuju na to da agomelatin ne utječe na pohranu monoamina i nema afiniteta za - i -adrenoreceptore, histaminergične, kolinergične, dopaminergične te benzodiazepinske receptore.
Binding to alpha-1 acid glycoprotein and to platelets is negligible ( 5%).
Vezanje na alfa-1 kiseli glikoprotein i trombocite je zanemarivo ( 5%).
Binding to hepatic receptors is, however, reduced compared to native t- PA, resulting in a prolonged half-life.
Vezanje na jetrene receptore je, međutim, smanjeno u odnosu na fiziološki t-PA, što rezultira produljenim poluvijekom.
BindRen 1 g film-coated tablets
BindRen 1 g filmom obložene tablete
BindRen 1 g tablets
BindRen 1 g tablete
BindRen 2 g granules
BindRen 2 g granule
BindRen 2 g granules BindRen 3 g granules colestilan
BindRen 2 g granule BindRen 3 g granule kolestilan
BindRen 2 g granules colestilan
BindRen 2 g granule kolestilan
BindRen 2 g granules: each sachet contains 2 g of colestilan.
BindRen 2 g granule: jedna vrećica sadrži 2 g kolestilana.
BindRen 3 g granules
BindRen 3 g granule
BindRen 3 g granules colestilan
BindRen 3 g granule kolestilan
BindRen 3 g granules: each sachet contains 3 g of colestilan.
BindRen 3 g granule: jedna vrećica sadrži 3 g kolestirana.
BindRen alone is not indicated for the control of hyperparathyroidism.
BindRen nije indiciran za kontrolu hiperparatireoidizma.
BindRen contains colestilan.
BindRen sadrži kolestilan.
BindRen does not contain calcium and your doctor may prescribe additional calcium tablets.
BindRen ne sadrži kalcij i liječnik Vam može dodatno propisati tablete kalcija. imate nenormalno visoke razine kalcija u krvi zbog prejake aktivnosti paratiroidnih žlijezda.
BindRen granules are white cylindrical granules.
BindRen granule bijele, cilindrične granule.
BindRen has no or negligible influence on the ability to drive or use machines.
BindRen ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
BindRen is not absorbed from the gastrointestinal tract but may affect the bioavailability or absorption rate of other medicinal products.
BindRen se ne apsorbira iz probavnog trakta, ali može utjecati na bioraspoloživost ili brzinu apsorpcije drugih lijekova.
Binet stage A
Binet stadij A
Binet stage B
Binet stadij B
Binet stage C
Binet stadij C
Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)
nekontrolirano prekomjerno kupovanje ili trošenje neumjerenost u jelu (uzimanje velikih količina hrane u kratkom vremenskom razdoblju) ili kompulzivno (prisilno) uzimanje hrane (uzimanje hrane u količini većoj nego što je uobičajeno i više od količine koja zadovoljava glad)
Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*
prejedanje (jedenje ogromnih količina hrane u kratkom razdoblju) ili kompulzivno jedenje (izjedanje veće količine hrane nego što je normalno i više nego je potrebno za utaženje gladi)
Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*
prejedanje (jedenje ogromnih količina hrane u kratkom razdoblju) ili kompulzivno jedenje (jedenje veće količine hrane nego što je normalno i više nego je potrebno za utaženje gladi)
Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*
prejedanje (jedenje velikih količina hrane u kratkom vremenskom periodu) ili kompulzivno jedenje (jedenje više nego što je normalno i potrebno za zadovoljavanje gladi)
binge eating1, compulsive shopping, delusion, hyperphagia1, hypersexuality, libido disorder, paranoia, pathological gambling, restlessness, delirium
prejedanje1, kompulzivno kupovanje, deluzije, hiperfagija1, hiperseksualnost, poremećaji libida, paranoja, patološka želja za kockanjem, nemir, delirij
Binocrit 1,000 IU/0.5 ml injection
Binocrit 1000 IU/0,5 ml injekcija
Binocrit 1,000 IU/0.5 ml solution for injection in a pre-filled syringe
Binocrit 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 1,000 IU/0.5 ml solution for injection in a pre-filled syringe Binocrit 2,000 IU/1 ml solution for injection in a pre-filled syringe Binocrit 3,000 IU/0.3 ml solution for injection in a pre-filled syringe Binocrit 4,000 IU/0.4 ml solution for injection in a pre-filled syringe Binocrit 5,000 IU/0.5 ml solution for injection in a pre-filled syringe Binocrit 6,000 IU/0.6 ml solution for injection in a pre-filled syringe Binocrit 7,000 IU/0.7 ml solution for injection in a pre-filled syringe Binocrit 8,000 IU/0.8 ml solution for injection in a pre-filled syringe Binocrit 9,000 IU/0.9 ml solution for injection in a pre-filled syringe Binocrit 10,000 IU/1 ml solution for injection in a pre-filled syringe Binocrit 20,000 IU/0.5 ml solution for injection in a pre-filled syringe Binocrit 30,000 IU/0.75 ml solution for injection in a pre-filled syringe
Binocrit 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 2000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 3000 IU/0,3 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 4000 IU/0,4 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 6000 IU/0,6 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 7000 IU/0,7 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 8000 IU/0,8 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 9000 IU/0,9 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 20 000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Binocrit 30 000 IU/0,75 ml otopina za injekciju u napunjenoj štrcaljki